Ian Mortimer, President & CEO of Xenon Pharmaceuticals Inc. (XENE), acquired 30,000 shares of the company on September 30, 2026. The transaction, valued at approximately $1.12 million, was executed at an average price of $37.38 per share.
This purchase by a senior executive is often interpreted as a strong signal of confidence in the company's future prospects. The move comes amidst other recent insider activity at Xenon, including a buy of 15,000 shares by Thomas Patrick Kelly on the same day.
In contrast, other executives have made sales in recent months, such as Christopher John Kenney and Steven Gannon, which can be attributed to various reasons including diversification or tax planning.